![]() ![]() use of novel combinations), have the potential to reduce or delay recurrence, and thus extend survival in patients with resected cutaneous melanoma.īempegaldesleukin (BEMPEG, NKTR-214) is an immunostimulatory interleukin-2 (IL-2) cytokine prodrug, engineered to deliver a controlled, sustained, and preferential IL-2 pathway signal. Nivolumab (NIVO), an immune checkpoint inhibitor (ICI), is a standard-of-care adjuvant therapy for patients with resected stage III/IV melanoma, with a 4-year recurrence-free survival (RFS) of 52%. Eggermont (Email address: of Translational Medicine 2022 20(1): 1īackground: Patients with stage III or IV melanoma are at high risk for recurrence following surgical resection. Lee Moffitt Cancer Center, Tampa, FL, USA, 4Department of Dermatology, University Hospital Essen, Essen, Germany, 5Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA, 6Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 7Department of Medical Oncology, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA, 8Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA, 9 Department of Medical Oncology, Ochsner Medical Center, New Orleans, LA, USA, 10Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia, 11formerly of Nektar Therapeutics, San Francisco, CA, USA, 12Nektar Therapeutics, San Francisco, CA, USA, 13Department of Medical Oncology, Westmead and Blacktown Hospitals and Melanoma Institute Australia, The University of Sydney, Sydney, Australia Correspondence: Alexander M.M. Pascale, Naples, Italy, 3Department of Cutaneous Oncology, H. ![]() PIVOT-12: A phase 3 randomized study of adjuvant bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO in completely resected cutaneous melanoma at high risk for recurrence Alexander M M Eggermont 1,*, Paolo A Ascierto 2, Nikhil I Khushalani 3, Dirk Schadendorf 4, Genevieve M Boland 5, Adi Diab 6, Jeffrey S Weber 7, Karl D Lewis 8, Daniel Johnson 9, Georgina V Long 10, Sue Currie 11, Mann Muhsin 12, Mary Tagliaferri 12, Matteo S Carlino 13 1Princess Máxima Center for Pediatric Oncology and the University Medical Center Utrecht, Utrecht, The Netherlands, 2Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |